HCB303

Asset

Trispecific immunotherapy targeting PD-L1 and CD47 while intercepting TIGIT ligands

Stage
Phase 1
Modality
Protein or enzyme
Target
CD47
1
Indication
0
Trials
1
Developer

Indications

1

In the full profile

  • Targets and what it contains3
  • Owner and partners1
  • Evidence for its targets3
  • Competitors7

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets